U.S. market Open. Closes in 4 hours 34 minutes

RETA | Reata Pharmaceuticals, Inc. Stock Fundamentals

(Stock Exchange: NASDAQ)
Analyzing fundamentals for RETA we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is very poor, Growth is desperately bad and Health is weak.

Valuation (3%)

Company Industry
P/E Ratio (TTM) -89.36 -23.05
PEG Ratio (TTM) -1.19 15.47
P/S Ratio (TTM) 269.17 49.46
P/B Ratio (TTM) 81.96 18.87
P/FCF Ratio (TTM) -26.32 -3.27
Price to 5YR AVG Earnings Ratio -23.56 -3.55
Price to 5YR AVG FCF Ratio -29.68 -9.37

Profitability (35%)

Company Industry
ROA (TTM) -15.93% -5.14%
ROE (TTM) 19.32% 16.69%
Net Profit Margin (TTM) -328.17% -1,583.93%
ROIC 5YR AVG 20.53% 15.15%

Growth (25%)

4QTR AVG 3YR AVG 5YR AVG
EPS 56.79% -83.70% -53.49%
Revenue 2,881.52% -35.00% -31.66%
Net Income 57.24% -104.87% -67.90%
Cash Flow -12.62% -76.25% -37.71%

Health (46%)

Company Industry
Current Ratio (TTM) 3.21 6.13
Quick Ratio (TTM) 2.82 5.85
D/E Ratio (TTM) 1.90 -15.81
Interest Coverage (TTM) -1.46 -1.57
Piotroski F-Score 3 5
Altman Z-Score 5.79 14.12
LTL to 5YR AVG FCF -0.53 0.17
Shares Outstanding Growth 5YR AVG 8.82% 123.44%
An error has occurred. This application may no longer respond until reloaded. Reload 🗙